Exchange: NASDAQ·Updated 04:21 AM EDT
VIVS logo

VIVSVivoSim Labs, Inc.

$0.4588
$0.0461
(9.13%)
Pre-Market
Prev Close $0.5049
Mkt Cap$2.02M
Vol35,841.00
News
all
press releases
Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus
The pharmaceutical industry loses billions each year on drug candidates that perform well in animal testing but ultimately fail in human trials, most often because of safety concerns. As regulators push for more predictive human-based testing models, companies developing next-generation preclinical technologies are beginning to attract growing attention from both pharmaceutical partners and investors.Shares of VivoSim Labs, Inc. (Nasdaq: VIVS) are climbing Wednesday after the company announced it received a $5 million milestone payment from Eli Lilly while also issuing fiscal 2027 guidance ...
AllPennyStocks.com
News Placeholder
More News
News Placeholder
Why Vivosim Labs Shares Are Rocketing on Wednesday?
VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.read more...
Benzinga
News Placeholder
Wall Street Turning Towards Momentum Narratives
Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR
24-7 Market News
News Placeholder
VivoSim Lands $5M from Eli Lilly as FDA's Animal-Testing Shift Fuels Projected 500%+ Revenue Explosion
VivoSim Labs (NASDAQ:VIVS) delivered two developments that could significantly strengthen its investment narrative: a $5 million milestone payment from Eli Lilly tied to a previously divested inflammatory bowel disease drug program, and guidance calling for more than 500% revenue growth in fiscal 2027 as demand accelerates for its human-based preclinical testing platform.
24-7 Market News
News Placeholder
Top Biotech Stocks To Follow Today - February 1st
Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...
MarketBeat
News Placeholder
Biotech Stocks To Keep An Eye On - January 31st
Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...
MarketBeat
News Placeholder
Biotech Stocks To Follow Today - January 30th
Danaher, VivoSim Labs, Moderna, Vaxcyte, and Dianthus Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...
MarketBeat
News Placeholder
Why Is VIVS Stock Up 79% Today?
VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.
Stocktwits
<
...
1
>

Advertisement|Remove ads.